ciprofibrate

Known as: 2-(4-(2,2-dichlorocyclopropyl)phenoxy)2-methylpropanoic acid, 2-(P-(2,2-Dichlorocyclopropyl)Phenoxy)-2-Methylpropionic Acid, Propanoic Acid, 2-(4-(2,2-Dichlorocyclopropyl)Phenoxy)-2-Methyl- 
A fibrate derivative with antilipidemic activity.
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Clofibric AcidFibric AcidsHypolipidemic AgentsPeroxisome Proliferators

Narrower (2)

LipanorOroxadin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver.
The multidrug resistance-associated proteins (Mrp) are ATP-dependent transporters that export a variety of conjugated and… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia.
The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) plays a key role in lipid metabolism and inflammation. Recently… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Application of comparative functional genomics to identify best-fit mouse models to study human cancer
Genetically modified mice have been extensively used for analyzing the molecular events that occur during tumor development. In… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression.
Fibrates are hypolipidemic drugs that affect the expression of genes involved in lipid metabolism by activating peroxisome… (More)
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.
BACKGROUND Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity.
Fibrates and glitazones are two classes of drugs currently used in the treatment of dyslipidemia and insulin resistance (IR… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3.
Glucuronide conjugation of xenobiotics containing a tertiary amine moiety represents a unique and important metabolic pathway for… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1996
1996
Novel lipid-lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate.
Vaccinium myrtillus L. (blueberry) leaf infusions are traditionally used as a folk medicine treatment of diabetes. To further… (More)
Is this relevant?
1994
1994
Effects of ciprofibrate on LDL metabolism in man.
This study examined the effects of ciprofibrate therapy (100 mg/day) on plasma lipids, lipoproteins and low density lipoprotein… (More)
Is this relevant?
1989
1989
Evaluation of liver cell proliferation during ciprofibrate-induced hepatocarcinogenesis.
To determine if the carcinogenic potential of peroxisome proliferators is dependent upon their ability to induce cell… (More)
Is this relevant?